Skip to main content
. 2021 Jan 11;2021:6655185. doi: 10.1155/2021/6655185

Table 3.

Treatment of patients infected with SARS-CoV-2 (N = 492).

Treatment Patients with AKI Patients without AKI p value
Diuretic 11 (30.56%) 18 (3.95%) <0.001
Quinolone 34 (94.44%) 389 (85.31%) 0.13
First- or second-generation cephalosporins 0.00 22 (4.82%) 0.18
Penicillin 8 (22.22%) 88 (19.30%) 0.67
Antiviral 34 (94.44%) 393 (86.18%) 0.16
Glucocorticoid 23 (63.89%) 135 (29.61%) <0.001
NSAID 8 (22.22%) 108 (23.68%) 0.84
PPI 23 (63.89%) 212 (46.49%) 0.04
Traditional Chinese medicine 2 (5.56%) 43 (9.43%) 0.44

Data are n/N (%), where N is the total number of patients with available data. p values comparing patients with AKI and without AKI are from chi-square or Mann–Whitney U test. SARS-CoV-2 = 2019 novel coronavirus; AKI = acute kidney injury; NSAID = nonsteroidal anti-inflammatory drugs; PPI = proton pump inhibitor.